An experimental drug is found to preferentially dilate autoregulatory coronary arterioles without affecting large conducting vessels. It is likely to:
Evoke coronary steal phenomenon
Mitigate classical angina but not variant angina
Produce tachycardia as an adverse effect
Useful in CHF